13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04990219 (ClinicalTrials.gov) | September 27, 2021 | 29/7/2021 | A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis | Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Lu AG06466;Drug: Placebo | H. Lundbeck A/S | NULL | Terminated | 18 Years | 70 Years | All | 37 | Phase 1 | United States;Germany |